These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 28107585)

  • 21. Potential impact of curative and preventive interventions toward hepatitis C elimination in people who inject drugs-A network modeling study.
    Zhu L; Thompson WW; Hagan L; Randall LM; Rudolph AE; Young AM; Havens JR; Salomon JA; Linas BP
    Int J Drug Policy; 2024 Aug; 130():104539. PubMed ID: 39033645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections.
    Bennett H; McEwan P; Sugrue D; Kalsekar A; Yuan Y
    PLoS One; 2015; 10(5):e0125846. PubMed ID: 25938458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?
    Lima VD; Rozada I; Grebely J; Hull M; Lourenco L; Nosyk B; Krajden M; Yoshida E; Wood E; Montaner JS
    PLoS One; 2015; 10(12):e0143836. PubMed ID: 26633652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A hepatitis C outbreak preceded the HIV outbreak among persons who inject drugs in Athens, Greece: Insights from a mathematical modelling study.
    Gountas I; Sypsa V; Papatheodoridis G; Paraskevis D; Kalamitsis G; Anagnostou O; Antaraki A; Fotiou A; Hatzakis A
    J Viral Hepat; 2019 Nov; 26(11):1311-1317. PubMed ID: 31322302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can hepatitis C elimination targets be sustained among people who inject drugs post-2030?
    Lanièce Delaunay C; Godin A; Kronfli N; Panagiotoglou D; Cox J; Alary M; Klein MB; Maheu-Giroux M
    Int J Drug Policy; 2021 Oct; 96():103343. PubMed ID: 34215459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HCV elimination among people who inject drugs. Modelling pre- and post-WHO elimination era.
    Gountas I; Sypsa V; Blach S; Razavi H; Hatzakis A
    PLoS One; 2018; 13(8):e0202109. PubMed ID: 30114207
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of hepatitis C virus (HCV) elimination strategies among people who inject drugs (PWID) in Tijuana, Mexico.
    Marquez LK; Fleiz C; Burgos JL; Cepeda JA; McIntosh C; Garfein RS; Kiene SM; Brodine S; Strathdee SA; Martin NK
    Addiction; 2021 Oct; 116(10):2734-2745. PubMed ID: 33620750
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction in the population prevalence of hepatitis C virus viraemia among people who inject drugs associated with scale-up of direct-acting anti-viral therapy in community drug services: real-world data.
    Palmateer NE; McAuley A; Dillon JF; McDonald S; Yeung A; Smith S; Barclay S; Hayes P; Shepherd SJ; Gunson RN; Goldberg DJ; Hickman M; Hutchinson SJ
    Addiction; 2021 Oct; 116(10):2893-2907. PubMed ID: 33651446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Incidence of primary hepatitis C infection among people who inject drugs during 2012-2020 in Athens, Greece.
    Roussos S; Bagos C; Angelopoulos T; Chaikalis S; Cholongitas E; Savvanis S; Papadopoulos N; Kapatais A; Chounta A; Ioannidou P; Deutsch M; Manolakopoulos S; Sevastianos V; Papageorgiou MV; Vlachogiannakos I; Mela M; Elefsiniotis I; Vrakas S; Karagiannakis D; Pliarchopoulou F; Psichogiou M; Paraskevis D; Vickerman P; Malliori M; Kalamitsis G; Papatheodoridis G; Hatzakis A; Sypsa V
    J Viral Hepat; 2024 Aug; 31(8):466-476. PubMed ID: 38742938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High rates of early HCV reinfection after DAA treatment in people with recent drug use attended at mobile harm reduction units.
    Valencia J; Alvaro-Meca A; Troya J; Cuevas G; Gutiérrez J; Morro A; Alvarez J; Pulido L; Cañamares I; Escobar I; Moreno S; Ryan P
    Int J Drug Policy; 2019 Oct; 72():181-188. PubMed ID: 31253391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C transmission and treatment as prevention - The role of the injecting network.
    Hellard M; McBryde E; Sacks Davis R; Rolls DA; Higgs P; Aitken C; Thompson A; Doyle J; Pattison P; Robins G
    Int J Drug Policy; 2015 Oct; 26(10):958-62. PubMed ID: 26072105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia.
    Hellard ME; Jenkinson R; Higgs P; Stoové MA; Sacks-Davis R; Gold J; Hickman M; Vickerman P; Martin NK
    Med J Aust; 2012 Jun; 196(10):638-41. PubMed ID: 22676879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrating HCV testing with HIV programs improves hepatitis C outcomes in people who inject drugs: A cluster-randomized trial.
    Solomon SS; Quinn TC; Solomon S; McFall AM; Srikrishnan AK; Verma V; Kumar MS; Laeyendecker O; Celentano DD; Iqbal SH; Anand S; Vasudevan CK; Saravanan S; Thomas DL; Sachdeva KS; Lucas GM; Mehta SH
    J Hepatol; 2020 Jan; 72(1):67-74. PubMed ID: 31604081
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
    Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L
    J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program.
    Kåberg M; Hammarberg A; Lidman C; Weiland O
    Infect Dis (Lond); 2017 Oct; 49(10):728-736. PubMed ID: 28574295
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis C virus micro-elimination in people who inject drugs: Challenges and chance in Taiwan and worldwide.
    Tai CM; Yu ML
    Kaohsiung J Med Sci; 2024 Feb; 40(2):112-118. PubMed ID: 38010851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HCV treatment rates and sustained viral response among people who inject drugs in seven UK sites: real world results and modelling of treatment impact.
    Martin NK; Foster GR; Vilar J; Ryder S; Cramp ME; Gordon F; Dillon JF; Craine N; Busse H; Clements A; Hutchinson SJ; Ustianowski A; Ramsay M; Goldberg DJ; Irving W; Hope V; De Angelis D; Lyons M; Vickerman P; Hickman M
    J Viral Hepat; 2015 Apr; 22(4):399-408. PubMed ID: 25288193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
    Scott N; Doyle JS; Wilson DP; Wade A; Howell J; Pedrana A; Thompson A; Hellard ME
    Int J Drug Policy; 2017 Sep; 47():107-116. PubMed ID: 28797497
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs.
    Bruggmann P; Grebely J
    Int J Drug Policy; 2015 Feb; 26 Suppl 1():S22-6. PubMed ID: 25245939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals.
    Martin NK; Vickerman P; Grebely J; Hellard M; Hutchinson SJ; Lima VD; Foster GR; Dillon JF; Goldberg DJ; Dore GJ; Hickman M
    Hepatology; 2013 Nov; 58(5):1598-609. PubMed ID: 23553643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.